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Chapter 6

Determination of an Immunocontraceptive
Peptide in a Wildlife Vaccine Formulation
David A. Goldade,* Jeffrey M. Kemp,I Jeanette R. O'Hare, and
Lowell A. Miller
USDA/APHIS/WS/National Wildlife Research Center, 4101 LaPorte Avenue,
Fort Collins, Colorado 80521
1Present address: Colorado Serum Company, 4950 York Street,
Denver, Colorado 80216
*E-mail: David.A.Goldade@aphis.usda.gov

Wildlife populations continue to grow despite the use
of traditional management techniques.
GonaCon™
Immunocontraceptive Vaccine is a vaccine used to reduce
reproduction in mammalian species, including white-tailed deer
(Odocoileus virginianus). The vaccine consists of synthetic
gonadotropin releasing hormone (GnRH) conjugated to a
mollusk hemocyanin (Concholepas concholepas) prepared
as an emulsion with mineral oil to promote a prolonged
immune response. Development of an analytical method for
determination of the active ingredient in the vaccine formulation
was complicated by the emulsion and conjugation of GnRH
to the carrier protein. Breaking the emulsion was achieved
chemically by addition of diethyl ether. The aqueous portion
containing the GnRH conjugate was cleaved enzymatically
with a protease (clostripain) at the arginine-proline site of
its peptide sequence. Hydrolysis produced a diagnostic eight
amino acid peptide fragment which was unique to GnRH and
easily quantified by LC/MS/MS. Typical recoveries of fortified
samples at the target concentration exceeded 90%.
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Introduction

Wildlife populations, in particular wild deer populations have been steadily
increasing since the early J 900 's when population estimations placed the number
of wild deer in the US at approximately 500,000 (I). Restocking and conservation
efforts were undertaken to replenish the populations. These efforts have been
extremely successful to the point that a serious overpopulation problem now exists,
particularly in urban and suburban areas (2). Current population estimates are
in the neighborhood of 20 million individuals. Population densities can reach as
much as 40 to I 00 individuals per square mile in some urban and suburban areas
(3). These high population densities can lead to severe wildlife management issues
including increased deer-vehicle collisions (4), damage to ornamental plants or
crops (5), degradation of habitat quality for other wildlife due to overgrazing (6,
7), and possible disease transmission to other wild or domestic animals as well as
human populations (8, 9).
Management techniques typically employed to minimize deer-human
conflicts in rural settings include culling, the use of scare devices, or exclusion
fences. Firing high powered rifles in urban areas has very little support from
members of the public who live in the areas where control is needed (JO).
Scare devices are either wholly ineffective or are only effective for a short time
before the animals become habituated to them (11, 12). Exclusion fences are
not practical in many settings, can be cost prohibitive, and must be extremely
tall in order to keep highly agile deer from jumping over them (13). Ecosystem
controls such as the introduction of predators is not feasible in urban settings
(14). A long-term management solution must include new tools in an integrated
approach. A technique such as immunocontraception used to limit reproduction
of local populations is such a tool.
GonaCon™ Immunocontraceptive Vaccine (hereafter GonaCon™) is an
immunocontraceptive vaccine registered with the Environmental Protection
Agency (EPA) under the Federal Insecticide, Fungicide, and Rodenticide Act
(FIFRA) for use with female white-tailed deer 1 year of age or older (15). In
addition to registration with EPA, use of this product requires registration within
each state and approval by the State natural resource agency responsible for
managing wildlife. Currently, it is only registered for use in New Jersey and
Maryland.
OonaConTM consists of a synthetic gonadotropin releasing hormone peptide
(GnRH) conjugated to a mollusk hemocyanin (blue protein or BP). The conjugated
protein is mixed with mineral oil and a surfactant to produce an emulsion
(16, 17). The final vaccine emulsion is delivered to the target animals via a 1
mL intra-muscular injection (17, 18). The conjugated protein stimulates the
production of antibodies that bind to endogenous GnRH. By binding to GnRH,
the antibodies reduce GnRH's ability to stimulate the production of sex hormones
such as estrogen, progesterone, and testosterone. As a result, all sexual activity is
decreased and the animals remain in a nonreproductive state as long as a sufficient
level of antibody activity is present.
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In order to support the continued registration of GonaCon™, an Enforcement
Analytical Method is required by the EPA. The method needed to be accurate and
reliable. It also needed to be sensitive enough to detect small differences in the
active ingredient content of the final vaccine.

Methods
Reagents
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Formic acid (LC-MS Grade), DL-dithiothreitol, 2,2,2-trifluoroethanol, and
calcium chloride dihydrate were all obtained from Sigma-Aldrich (St. Louis,
MO). Acetonitrile (Optima Grade), diethyl ether (anhydrous), sodium phosphate
monobasic, and potassium hydroxide were obtained from Fisher Scientific
(Pittsburgh, PA). Clostripain (87 units/mg dry weight; Endoproteinase-Arg-C)
was purchased from Worthington Biochemical (Lakewood, NJ). Gonadotropin
releasing hormone (GnRH; [pE]HW SYG LRP GGC-CONH2; 95.42%
pure) was synthesized by GL Biochem (Shanghai, China).
Peptide-1
([Pyr]HWSYGLR-Acid; 97.39% pure) was synthesized by Pi Proteomics
(Huntsville, AL).
The mobile phase consisted of a mixture of 0.1% formic acid in deionized
water and acetonitrile. Deionized water was purified using an E-Pure water
purification system (Barnstead, Dubuque, IA). The sample extraction solution was
prepared by combining approximately 0.36 g of sodium phosphate monobasic
and 40 mg of DL-dithiothreitol in 60 mL deionized water. The pH was adjusted
to approximately 7.6 with a solution of 1M potassium hydroxide. To this solution
5 mL of 2,2,2-trifluoroethanol was added before diluting to a final volume of
I 00-mL with deionized water. The enzyme activation solution was prepared
by combining approximately 15 mg of calcium chloride dihydrate and 40 mg
of DL-dithiothreitol. The solution was diluted to 100 mL with deionized water
before use.
A concentrated stock solution of GnRH and Peptide- I was prepared by
weighing 1.000 mg of each and dissolving them in 5.00 mL of deionized water.
Working standards, ranging in concentration from 10 ng/mL to 2 µg/mL, were
prepared by dilution of stock solutions with a solution of 9: 1 0.1 % formic acid
in deionized water:O. l % formic acid in acetonitrile. All standard solutions were
stored at 5°C prior to use. A representative chromatogram is shown in Figure 1.
Sample Analysis

Breaking the Emulsion
GonaCon™ vaccine aliquots (0.5 g) were placed in 15-mL glass centrifuge
tubes. One milliliter of extraction solution was added to each sample. The
sample was vortexed to suspend the vaccine material followed by centrifugation
at approximately 5,000 g for 2 minutes. Diethyl ether was used to break the
emulsion and separate the mixture into an organic and aqueous layer. This was
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accomplished by adding three successive 5 mL aliquots of ether followed by a
vortexing and centrifugation step to separate the organic and aqueous layers.
The upper, organic layer was discarded and the aqueous layer was transferred
to a 5-mL volumetric flask and diluted to produce a solution containing 5%
trifluoroethanol in phosphate buffer.
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Figure 1. Chromatogram of a 500 nglml standard solution.

Enzymatic Cleavage
A solution of activated clostripain was prepared by weighing approximately
0.25 mg of clostripain into a 1.5-mL microcentrifuge tube and adding I mL of
enzyme activation solution. A 50 µL aliquot of sample extract was removed and
reacted with 50 µL of the clostripain solution in I mL of extraction solution to
produce the peptide fragment. The enzyme reaction was conducted in a water bath
held at approximately 25 °C for two hours. Following completion of the reaction,
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1 mL of a solution of 8:2 0.1 % formic acid in deionized water:0.1 % formic acid
in acetonitrile was added and the sample was centrifuged to remove any heavy
protein fragments. This clarified solution was injected into the LC/MS/MS and the
concentration of the diagnostic peptide fragment was quantified. Each sample was
analyzed for both total GnRH content and free (or unconjugated) GnRH content
by preparing a second sample which contained all of the components except the
clostripain.

High-Performance Liquid Chromatography Tandem Mass Spectrometry
The analytical system consisted of an Agilent 1200 liquid chromatograph
coupled to an Agilent 641 OA-2K triple quadrapole mass spectrometer (Palo
Alto, CA). Instrumental parameters are listed in Table 1. The mass spectrometer
was operated in the multiple reaction monitoring (MRM) mode (Table II). The
precursor ion for both GnRH and Peptide-I had a z value of 2. Therefore, the base
peak for each was found at half the mass of the molecule. Following collision in
the mass spectrometer, the product ions were found to have z values of l. This led
to a situation in which the product ions had larger m/z than the precursor ions for
the quantification transition for each analyte. The proposed fragment ions can be
seen in Figures 2 and 3. The m/z of the precursor ions are given in the lower left
comer of each figure. The lines indicate the site of fragmentation for each product
ion as well as the corresponding m/z value for each. The calibration standards ( 10
- 2,000 ng/mL) were injected in triplicate and subjected to a weighted quadratic
regression. Quantification was accomplished by comparing analyte responses to
the external standard calibration curve.
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Figure 2. Mass fragmentation of GnRH
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Figure 3. Mass fragmentation of Peptide-I.

Quality Control Samples and Fortification of Controls

A sham vaccine was prepared in the same manner as the GonaCon vaccine.
This sham contained all of the components except GnRH and was prepared using
the same protocols as the vaccine samples. The sham was fortified with a solution
of GnRH in deionized water to produce fortification levels 50% above and below
the target level for the vaccine (300 µg/mL). The quality control samples were
extracted and analyzed using the same procedure described above.

Results and Discussion
Enzymatic Cleavage

The GonaCon™ vaccine is manufactured by conjugating the synthetic
GnRH peptide to a mollusk hemocyanin protein via a sulfo-SMCC linker. Direct
measurement of the fully conjugated protein was not possible due to the mass
of the BP (approx.. 8 mDa). Attempts were made to analyze the final vaccine
through the use of near infrared transflectance. This approach proved to be
unfeasible possibly due to the high background created by the BP. The GnRH
could easily be measured in solutions via HPLC, but not when linked to BP.
The use of this linker produced a very stable and rugged link between the two
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components of the vaccine. However, this linkage is irreversible. Various
solvents, acids, bases, and buffer treatments were investigated in an attempt to
break this linkage. All efforts were unsuccessful. Clostripain is a proteinase
isolated from Clostridium histolyticum which is highly specific for the carboxyl
peptide bond of arginine and cleaves the GnRH at the cysteine residue in the
conjugate (Figure 2) (19). This produces a smaller fragment of GnRH which has
been called Peptide-I. Peptide- I results from one GnRH molecule in a directly
proportional relationship. Treatment of the sham vaccine with clostripain did not
produce any measurable Peptide-I. By use of this enzyme, direct measurement of
GnRH content in GonaCon vaccine was accomplished.

Table I. Instrument parameters
Parameter
Mobile Phase:

Conditions
A= 0.1 % formic acid in deionized water
B = 0.1 % formic acid in acetonitri le

Gradient:

Time

%A

%B

0.0

90

10

1.0

90

10

5.0

60

40

5.5

10

90

Flow Rate:

0.5 mL/minute

Injection Volume:

20 µL

Column:

Agilent Rapid Resolution HT Zorbax SB-C3, 100 mm x
3.0 mm i.d., 1.8 µm

Column Temperature:

80 °C

Detector Gas:

Nitrogen; 350 °C; 12.0 L/minute

Nebulizer Pressure:

40 psi

Capillary Voltage:

4000

MS 1 Resolution:

Wide

MS2 Resolution:

Unit

Run Time:

10 minutes

Post Time:

3 minutes

y
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Table II. Multiple reaction monitoring transitions
Compound

GnRH

Peptide-I

Transition

Dwell (ms)

Fragmentor
(v)

Collision
Energy (v)

672.0 ---+ 908.3

75

132

24

672.0 ---+ 249.1

75

132

32

515.4---+ 595.3

75

122

22

515.4---+ 249.0

75

122

20

Additional problems were encountered while selecting the final extraction
solution. The conjugated protein proved to be difficult to cleave with clostripain.
Various buffers were used in an attempt to maximize the recovery of Peptide-!
from the GonaCon conjugate. It was hypothesized that the protein could be
present in a folded conformation which might hinder the ability of the clostripain
to cleave it. The use of 2,2,2-trifluoroethanol provided a minor denaturing effect
which permitted the clostripain to cleave the GnRH. The enzyme system was
optimized by investigation of the concentration of 2,2,2-trifluoroethanol which
would permit the clostripain to still function while denaturing the conjugated
GonaCon. A solution of 5% was found to be optimal. The time needed for the
clostripain to cleave all of the GnRH present was also optimized. A reaction time
of two hours was found to be sufficient for greater than 99% cleavage.

Table III. Analytical recoveries of free and total GnRH in sham vaccine
quality control samples (n=7)
Range(%)

Mean {°/o)

Std. Dev. (%)

CV(%)

150

91.3 - 103

99.3

4.1

4.1

450

94.5 - 101

98.2

2.3

2.3

150

106 - 127

116

11

9.5

450

110 - 124

117

6.2

5.3

Fortification Level
(µgig)
Free GnRH

Total GnRH

Quality Control Results
Mean recoveries of free and total GnRH in sham vaccine (n=7) quality control
samples were excellent (Table Ill).
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Method Limit of Detection

The method limit of detection (MLOD) was estimated from the mean
chromatographic response at the retention time of the parent (GnRH) or product
(Peptide-I) peptide plus three times the response standard deviation from seven
replicate control samples. The mean and standard deviation for GnRH was
measured and found to be 3.881±0.335 ng/mL. The mean and standard deviation
for Peptide- I was measured and found to be 1.577±0.458 ng/mL. Using these
values, the MLOD for GnRH was estimated to be 2.1 µgig and the MLOD for
Peptide-I was 1.6 µg/g.
GnRH Determination in GonaCon Vaccine

Six replicate samples of a formulated GonaCon vaccine with a target content
of 300 µg/g were analyzed by the procedures outlined above. The range of
observed values was 151 to 199 µg/g. The mean and standard deviation were 178
µg/g and 18 µg/g respectively.

Conclusion
A highly selective and sensitive method for the determination of GnRH in
GonaCon vaccines has been detailed. The method is repeatable and accurate. Use
of this method will permit further investigation of the manufacturing and storage
stability of this important wildlife management tool.
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